Kyverna Therapeutics (KYTX) Accounts Payables (2023 - 2026)

Kyverna Therapeutics' Accounts Payables history runs 4 years deep, the most recent figure standing at $11.6 million for Q1 2026.

• Quarterly Accounts Payables rose 36.96% year-over-year to $11.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.6 million (up 36.96% YoY) and the FY2025 annual result came in at $5.3 million, up 14.75% from the prior year.
• Accounts Payables was $11.6 million for Q1 2026 at Kyverna Therapeutics, up from $5.3 million in the prior quarter.
• Across five years, Accounts Payables topped out at $11.6 million in Q1 2026 and bottomed at $3.0 million in Q3 2025.
• A 4-year average of $7.0 million and a median of $6.4 million in 2024 frame the typical range for Accounts Payables.
• Peak annual rise in Accounts Payables reached 104.01% in 2025, while the deepest fall reached 69.63% in 2025.
• Kyverna Therapeutics' Accounts Payables stood at $4.4 million in 2023, then grew by 6.1% to $4.6 million in 2024, then grew by 14.75% to $5.3 million in 2025, then surged by 118.68% to $11.6 million in 2026.
• Business Quant data shows KYTX's Accounts Payables at $11.6 million in Q1 2026, $5.3 million in Q4 2025, and $3.0 million in Q3 2025.